These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 34359801)

  • 41. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma.
    Martin RC; McFarland K; Ellis S; Velanovich V
    J Am Coll Surg; 2012 Sep; 215(3):361-9. PubMed ID: 22726894
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Irreversible Electroporation for Nonthermal Tumor Ablation in Patients with Locally Advanced Pancreatic Cancer: Initial Clinical Experience in Japan.
    Sugimoto K; Moriyasu F; Tsuchiya T; Nagakawa Y; Hosokawa Y; Saito K; Tsuchida A; Itoi T
    Intern Med; 2018 Nov; 57(22):3225-3231. PubMed ID: 29984761
    [TBL] [Abstract][Full Text] [Related]  

  • 43. First Delayed Resection Findings After Irreversible Electroporation (IRE) of Human Localised Renal Cell Carcinoma (RCC) in the IRENE Pilot Phase 2a Trial.
    Wendler JJ; Ricke J; Pech M; Fischbach F; Jürgens J; Siedentopf S; Roessner A; Porsch M; Baumunk D; Schostak M; Köllermann J; Liehr UB
    Cardiovasc Intervent Radiol; 2016 Feb; 39(2):239-50. PubMed ID: 26341653
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Irreversible electroporation of pancreatic adenocarcinoma: a primer for the radiologist.
    Rashid MF; Hecht EM; Steinman JA; Kluger MD
    Abdom Radiol (NY); 2018 Feb; 43(2):457-466. PubMed ID: 29051982
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
    Higuchi M; Owada Y; Inoue T; Watanabe Y; Yamaura T; Fukuhara M; Hasegawa T; Suzuki H
    World J Surg Oncol; 2016 Sep; 14(1):238. PubMed ID: 27595749
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of combination therapies in the management of locally advanced pancreatic cancer: Induction chemotherapy followed by irreversible electroporation vs radiofrequency ablation.
    He C; Wang J; Zhang Y; Cai Z; Lin X; Li S
    Cancer Med; 2020 Jul; 9(13):4699-4710. PubMed ID: 32410380
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Application of Irreversible Electroporation Ablation as Adjunctive Treatment for Margin Enhancement: Safety and Efficacy.
    Simmerman E; Chung J; Lawson A; Kruse E
    J Surg Res; 2020 Feb; 246():260-268. PubMed ID: 31610354
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone.
    Afzal MZ; Mabaera R; Shirai K
    J Immunother Cancer; 2018 Feb; 6(1):13. PubMed ID: 29433557
    [TBL] [Abstract][Full Text] [Related]  

  • 49. OX40 agonist combined with irreversible electroporation synergistically eradicates established tumors and drives systemic antitumor immune response in a syngeneic pancreatic cancer model.
    Zhang QW; Guo XX; Zhou Y; Wang QB; Liu Q; Wu ZY; Ding XY
    Am J Cancer Res; 2021; 11(6):2782-2801. PubMed ID: 34249428
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A prospective Phase 2a pilot study investigating focal percutaneous irreversible electroporation (IRE) ablation by NanoKnife in patients with localised renal cell carcinoma (RCC) with delayed interval tumour resection (IRENE trial).
    Wendler JJ; Porsch M; Nitschke S; Köllermann J; Siedentopf S; Pech M; Fischbach F; Ricke J; Schostak M; Liehr UB
    Contemp Clin Trials; 2015 Jul; 43():10-9. PubMed ID: 25962890
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.
    Martin RC; Kwon D; Chalikonda S; Sellers M; Kotz E; Scoggins C; McMasters KM; Watkins K
    Ann Surg; 2015 Sep; 262(3):486-94; discussion 492-4. PubMed ID: 26258317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy.
    Ansari D; Kristoffersson S; Andersson R; Bergenfeldt M
    Scand J Gastroenterol; 2017 Nov; 52(11):1165-1171. PubMed ID: 28687047
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review.
    Paiella S; Salvia R; Ramera M; Girelli R; Frigerio I; Giardino A; Allegrini V; Bassi C
    Gastroenterol Res Pract; 2016; 2016():4508376. PubMed ID: 26981115
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy of irreversible electroporation ablation combined with natural killer cells in treating locally advanced pancreatic cancer.
    Pan Q; Hu C; Fan Y; Wang Y; Li R; Hu X
    J BUON; 2020; 25(3):1643-1649. PubMed ID: 32862617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Percutaneous Irreversible Electroporation (IRE) of Hepatic Malignancy: A Bi-institutional Analysis of Safety and Outcomes.
    Mafeld S; Wong JJ; Kibriya N; Stenberg B; Manas D; Bassett P; Aslam T; Evans J; Littler P
    Cardiovasc Intervent Radiol; 2019 Apr; 42(4):577-583. PubMed ID: 30465255
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Combining intraoperative ultrasound-guided irreversible electroporation with chemotherapy for treating locally advanced pancreatic cancer: a clinical report of 64 cases].
    Li SP; He CB; Wang J; Mao YZ; Lao XM; Cui BK; Lin XJ
    Zhonghua Wai Ke Za Zhi; 2020 Oct; 58(10):787-792. PubMed ID: 32993267
    [No Abstract]   [Full Text] [Related]  

  • 57. Image-guided in situ cancer vaccination with combination of multi-functional nano-adjuvant and an irreversible electroporation technique.
    Han JH; Lee YY; Shin HE; Han J; Kang JM; James Wang CP; Park JH; Kim SN; Yoon JH; Kwon HK; Park DH; Park TE; Choy YB; Kim DH; Kim TH; Min J; Kim IH; Park CG; Han DK; Park W
    Biomaterials; 2022 Oct; 289():121762. PubMed ID: 36058029
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    Wang X; Su Z; Lyu T; Figini M; Procissi D; Shangguan J; Sun C; Wang B; Shang N; Gu S; Ma Q; Gordon AC; Lin K; Wang J; Lewandowski RJ; Salem R; Yaghmai V; Larson AC; Zhang Z
    Radiology; 2018 Apr; 287(1):137-145. PubMed ID: 29232185
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Physical and Chemical Enhancement of and Adaptive Resistance to Irreversible Electroporation of Pancreatic Cancer.
    Shao Q; Liu F; Chung C; Elahi-Gedwillo K; Provenzano PP; Forsyth B; Bischof JC
    Ann Biomed Eng; 2018 Jan; 46(1):25-36. PubMed ID: 28983745
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Unveiling the immunosuppressive landscape of pancreatic ductal adenocarcinoma: implications for innovative immunotherapy strategies.
    Guo S; Wang Z
    Front Oncol; 2024; 14():1349308. PubMed ID: 38590651
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.